{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:02:13Z","timestamp":1773680533691,"version":"3.50.1"},"reference-count":51,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,3,13]]},"abstract":"<jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and\n                            available treatments for migraine prevention. Patients do not respond\n                            alike and many countries have reimbursement policies, which hinder\n                            treatments to those who might respond. This study aimed to investigate\n                            clinical factors associated with good and excellent response to\n                            anti-CGRP MAbs at 6 months.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>European multicentre, prospective, real-world study, including\n                            high-frequency episodic or chronic migraine (CM) patients treated since\n                            March 2018 with anti-CGRP MAbs. We defined good and excellent responses\n                            as \u226550%\u2009and \u226575% reduction in monthly headache days (MHD) at 6 months,\n                            respectively. Generalised mixed-effect regression models (GLMMs) were\n                            used to identify variables independently associated with treatment\n                            response.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Of the 5818 included patients, 82.3% were females and the median age\n                            was 48.0 (40.0\u201355.0) years. At baseline, the median of MHD was 20.0\n                            (14.0\u201328.0) days\/months and 72.2% had a diagnosis of CM. At 6 months\n                            (n=4963), 56.5% (2804\/4963) were good responders and 26.7% (1324\/4963)\n                            were excellent responders. In the GLMM model, older age (1.08 (95% CI\n                            1.02 to 1.15), p=0.016), the presence of unilateral pain (1.39 (95% CI\n                            1.21 to 1.60), p&lt;0.001), the absence of depression (0.840 (95% CI\n                            0.731 to 0.966), p=0.014), less monthly migraine days (0.923 (95% CI\n                            0.862 to 0.989), p=0.023) and lower Migraine Disability Assessment at\n                            baseline (0.874 (95% CI 0.819 to 0.932), p&lt;0.001) were predictors of\n                            good response (AUC of 0.648 (95% CI 0.616 to 0.680)). These variables\n                            were also significant predictors of excellent response (AUC of 0.691\n                            (95% CI 0.651 to 0.731)). Sex was not significant in the GLMM\n                            models.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>This is the largest real-world study of migraine patients treated\n                            with anti-CGRP MAbs. It provides evidence that higher migraine frequency\n                            and greater disability at baseline reduce the likelihood of responding\n                            to anti-CGRP MAbs, informing physicians and policy-makers on the need\n                            for an earlier treatment in order to offer the best chance of treatment\n                            success.<\/jats:p>\n                    <\/jats:sec>","DOI":"10.1136\/jnnp-2023-333295","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:19:16Z","timestamp":1718821156000},"page":"jnnp-2023-333295","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Redefining migraine prevention: early treatment with anti-CGRP monoclonal\n                        antibodies enhances response in the real world"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-0267","authenticated-orcid":false,"given":"Edoardo","family":"Caronna","sequence":"first","affiliation":[]},{"given":"Victor Jos\u00e9","family":"Gallardo","sequence":"additional","affiliation":[]},{"given":"Gabriella","family":"Egeo","sequence":"additional","affiliation":[]},{"given":"Manuel Mill\u00e1n","family":"V\u00e1zquez","sequence":"additional","affiliation":[]},{"given":"Candela Nieves","family":"Castellanos","sequence":"additional","affiliation":[]},{"given":"Javier A","family":"Membrilla","sequence":"additional","affiliation":[]},{"given":"Gloria","family":"Vaghi","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Rodr\u00edguez-Montolio","sequence":"additional","affiliation":[]},{"given":"Neus","family":"Fabregat Fabra","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"S\u00e1nchez-Caballero","sequence":"additional","affiliation":[]},{"given":"Alex","family":"Jaimes S\u00e1nchez","sequence":"additional","affiliation":[]},{"given":"Albert","family":"Mu\u00f1oz-Vendrell","sequence":"additional","affiliation":[]},{"given":"Renato","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Gabriel","family":"G\u00e1rate","sequence":"additional","affiliation":[]},{"given":"Y\u00e9sica","family":"Gonz\u00e1lez-Osorio","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Guisado-Alonso","sequence":"additional","affiliation":[]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[]},{"given":"Cem","family":"Thunstedt","sequence":"additional","affiliation":[]},{"given":"Iris","family":"Fern\u00e1ndez-L\u00e1zaro","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Torres-Ferr\u00fas","sequence":"additional","affiliation":[]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[]},{"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[]},{"given":"Raquel Lamas","family":"P\u00e9re","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9 Ruiz","family":"Castrillo","sequence":"additional","affiliation":[]},{"given":"Roberto De","family":"Icco","sequence":"additional","affiliation":[]},{"given":"Grazia","family":"Sances","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Broadhurst","sequence":"additional","affiliation":[]},{"given":"Hui Ching","family":"Ong","sequence":"additional","affiliation":[]},{"given":"Andrea G\u00f3mez","family":"Garc\u00eda","sequence":"additional","affiliation":[]},{"given":"Sergio","family":"Campoy","sequence":"additional","affiliation":[]},{"given":"Jordi","family":"Sanahuja","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo","family":"Cabral","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Beltr\u00e1n Blasco","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Waliszewska-Pros\u00f3\u0142","sequence":"additional","affiliation":[]},{"given":"Liliana","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Almudena","family":"Layos-Romero","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Luzeiro","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Dorado","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda Rocio","family":"\u00c1lvarez Escudero","sequence":"additional","affiliation":[]},{"given":"Arne","family":"May","sequence":"additional","affiliation":[]},{"given":"Alba","family":"L\u00f3pez-Bravo","sequence":"additional","affiliation":[]},{"given":"Isabel Pav\u00e3o","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Christina","family":"Sundal","sequence":"additional","affiliation":[]},{"given":"Pablo","family":"Irimia","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Lozano Ros","sequence":"additional","affiliation":[]},{"given":"Ana Beatriz","family":"Gago-Veiga","sequence":"additional","affiliation":[]},{"given":"Fernando Velasco","family":"Juanes","sequence":"additional","affiliation":[]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[]},{"given":"Elisa","family":"Cuadrado-Godia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-1064","authenticated-orcid":false,"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[]},{"given":"Mariano","family":"Huerta-Villanueva","sequence":"additional","affiliation":[]},{"given":"Jaime","family":"Rodriguez-Vico","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Viguera Romero","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Obach","sequence":"additional","affiliation":[]},{"given":"Sonia","family":"Santos-Lasaosa","sequence":"additional","affiliation":[]},{"given":"Mona","family":"Ghadiri-Sani","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[]},{"given":"Javier","family":"D\u00edaz-de-Ter\u00e1n","sequence":"additional","affiliation":[]},{"given":"Samuel","family":"D\u00edaz Insa","sequence":"additional","affiliation":[]},{"given":"Carmen Gonz\u00e1lez","family":"Oria","sequence":"additional","affiliation":[]},{"given":"Piero","family":"Barbanti","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"2024061408370048000_jnnp-2023-333295v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"2024061408370048000_jnnp-2023-333295v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"2024061408370048000_jnnp-2023-333295v1.3","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","article-title":"The impact of anti-CGRP Monoclonal antibodies in resistant migraine patients: a real-world evidence observational study","volume":"268","author":"Torres-Ferr\u00fas","year":"2021","journal-title":"J Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ene.15740","article-title":"Efficacy and safety of Fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: prospective, multicenter, real-world data from a Greek Registry","volume":"30","author":"Argyriou","year":"2023","journal-title":"Eur J Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.5","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-023-01561-w","article-title":"Early and sustained efficacy of Fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life Friend2 study","volume":"24","author":"Barbanti","year":"2023","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.6","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01247-1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)","volume":"22","author":"Vernieri","year":"2021","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/head.14032","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"key":"2024061408370048000_jnnp-2023-333295v1.8","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of Erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.9","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417739584"},{"key":"2024061408370048000_jnnp-2023-333295v1.10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neulet.2017.11.034","article-title":"Expression of CGRP neurotransmitter and vascular genesis marker mRNA is age-dependent in superior Cervical ganglia of Senescence-accelerated prone mice","volume":"664","author":"Mitsuoka","year":"2018","journal-title":"Neurosci Lett"},{"key":"2024061408370048000_jnnp-2023-333295v1.11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/head.13774","article-title":"How does migraine change after 10 years? A clinical cohort follow-up analysis","volume":"60","author":"Caronna","year":"2020","journal-title":"Headache"},{"key":"2024061408370048000_jnnp-2023-333295v1.12","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01111-8","article-title":"From transformation to Chronification of migraine: pathophysiological and clinical aspects","volume":"21","author":"Torres-Ferr\u00fas","year":"2020","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of Erenumab: A retrospective cohort study","volume":"40","author":"Kanaan","year":"2020","journal-title":"Cephalalgia"},{"key":"2024061408370048000_jnnp-2023-333295v1.14","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP Monoclonal antibodies in chronic migraine with medication Overuse: real-life effectiveness and predictors of response at 6 months","volume":"22","author":"Caronna","year":"2021","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/ene.15236","article-title":"Clinic and genetic predictors in response to Erenumab","volume":"29","author":"Zecca","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.16","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP Monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.17","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221095902","article-title":"The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven Scoping literature review","volume":"15","author":"Gottschalk","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"2024061408370048000_jnnp-2023-333295v1.18","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01336-1","article-title":"Impact of age and sex on the efficacy of Fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3B FOCUS study","volume":"22","author":"MaassenVanDenBrink","year":"2021","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.19","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1111\/ene.15458","article-title":"Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study","volume":"29","author":"Gonzalez-Martinez","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.20","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010143","article-title":"Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: A systematic review of real-world data","volume":"12","author":"Pavelic","year":"2022","journal-title":"Cells"},{"key":"2024061408370048000_jnnp-2023-333295v1.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286453","article-title":"Gender bias in clinical trials of biological agents for migraine: A systematic review","volume":"18","author":"Alonso-Moreno","year":"2023","journal-title":"PLoS One"},{"key":"2024061408370048000_jnnp-2023-333295v1.22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/cts.12764","article-title":"Clinical trial Generalizability assessment in the big data era: A review","volume":"13","author":"He","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2024061408370048000_jnnp-2023-333295v1.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"2024061408370048000_jnnp-2023-333295v1.24","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"2024061408370048000_jnnp-2023-333295v1.25","doi-asserted-by":"crossref","unstructured":"Sacco S , Braschinsky M , Ducros A , et al . European\n                            headache Federation consensus on the definition of resistant and\n                            refractory migraine. J Headache Pain 2020;21.\n                            doi:10.1186\/s10194-020-01130-5","DOI":"10.1186\/s10194-020-01130-5"},{"key":"2024061408370048000_jnnp-2023-333295v1.26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"2024061408370048000_jnnp-2023-333295v1.27","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"2024061408370048000_jnnp-2023-333295v1.28","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i05"},{"key":"2024061408370048000_jnnp-2023-333295v1.29","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.774341","article-title":"Gender differences in 3-month outcomes of Erenumab treatment\u2014study on efficacy and safety of treatment with Erenumab in men","volume":"12","author":"Ornello","year":"2021","journal-title":"Front Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamaneurol.2023.2335","article-title":"Considering patient sex in prescribing CGRP receptor antagonists for short-term treatment of migraine","volume":"80","author":"Porreca","year":"2023","journal-title":"JAMA Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.31","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1007\/s10072-022-06190-w","article-title":"Comparison of efficacy and safety of Erenumab between over and under 65-year-old refractory migraine patients: a pivotal study","volume":"43","author":"Cetta","year":"2022","journal-title":"Neurol Sci"},{"key":"2024061408370048000_jnnp-2023-333295v1.32","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and safety of anti-CGRP Monoclonal antibodies in patients over 65 years: a real-life Multicentre analysis of 162 patients","volume":"24","author":"Mu\u00f1oz-Vendrell","year":"2023","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1474-4422(23)00206-5","article-title":"Migraine in older adults","volume":"22","author":"Hugger","year":"2023","journal-title":"Lancet Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.34","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01456-2","article-title":"Efficacy of Erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation","volume":"23","author":"Lowe","year":"2022","journal-title":"J Headache Pain"},{"key":"2024061408370048000_jnnp-2023-333295v1.35","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416636055"},{"key":"2024061408370048000_jnnp-2023-333295v1.36","unstructured":"European Medicines Agency . Assessment report\n                            Aimovig, Available:\n                            https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/aimovig-epar-public-assessment-report_en.pdf"},{"key":"2024061408370048000_jnnp-2023-333295v1.37","unstructured":"European Medicines Agency . Assessment report Ajovy,\n                            Available:\n                            https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ajovy-epar-public-assessment-report_en.pdf"},{"key":"2024061408370048000_jnnp-2023-333295v1.38","unstructured":"European Medicines Agency . Assessment report\n                            Emgality, Available:\n                            https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/emgality-epar-public-assessment-report_en.pdf"},{"key":"2024061408370048000_jnnp-2023-333295v1.39","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/ene.15197","article-title":"Rapid response to Galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study","volume":"29","author":"Vernieri","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.40","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093218","article-title":"Predictors of response to Fremanezumab in migraine patients with at least three previous preventive failures: post hoc analysis of a prospective, multicenter, real-world Greek Registry","volume":"12","author":"Argyriou","year":"2023","journal-title":"J Clin Med"},{"key":"2024061408370048000_jnnp-2023-333295v1.41","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"2024061408370048000_jnnp-2023-333295v1.42","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.973226","article-title":"Cranial autonomic symptoms and response to Monoclonal antibodies targeting the calcitonin gene-related peptide pathway: A real-world study","volume":"13","author":"De Matteis","year":"2022","journal-title":"Front Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.43","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26472"},{"key":"2024061408370048000_jnnp-2023-333295v1.44","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10072-023-06683-2","article-title":"Predictors of response to Galcanezumab in patients with chronic migraine: a real-world prospective observational study","volume":"44","author":"Lee","year":"2023","journal-title":"Neurol Sci"},{"key":"2024061408370048000_jnnp-2023-333295v1.45","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/ene.15816","article-title":"Patterns of response to anti-calcitonin gene-related peptide Monoclonal antibodies during first 6 months of treatment in resistant migraine patients: impact on outcome","volume":"30","author":"Torres-Ferrus","year":"2023","journal-title":"Eur J Neurol"},{"key":"2024061408370048000_jnnp-2023-333295v1.46","doi-asserted-by":"crossref","unstructured":"Bottiroli S , De Icco R , Vaghi G , et al .\n                            Psychological predictors of negative treatment outcome with Erenumab in\n                            chronic migraine: data from an open label long-term prospective study. J\n                            Headache Pain 2021;22.\n                            doi:10.1186\/s10194-021-01333-4","DOI":"10.1186\/s10194-021-01333-4"},{"key":"2024061408370048000_jnnp-2023-333295v1.47","doi-asserted-by":"publisher","DOI":"10.1111\/head.13843"},{"key":"2024061408370048000_jnnp-2023-333295v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"2024061408370048000_jnnp-2023-333295v1.49","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3B trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"2024061408370048000_jnnp-2023-333295v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"2024061408370048000_jnnp-2023-333295v1.51","doi-asserted-by":"publisher","DOI":"10.1111\/head.12498"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-333295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:19:33Z","timestamp":1718821173000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-333295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":51,"alternative-id":["10.1136\/jnnp-2023-333295"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-333295","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}